ABP 501 is a biosimilar candidate to Humira (adalimumab), an anti-tumor necrosis factor-alpha (TNF-α) monoclonal antibody, which is approved in many regions for the treatment of several inflammatory
Several promising natural products being developed as the active pharmaceutical ingredients of investigational drug products have encountered roadblocks that nanotechnology may be able to address. One of these
Under the terms of the agreement, Seres and Emulate will work to further advance Emulate’s Intestine-Chip platform, a micro-engineered, living-tissue-based system that models the human intestine. Seres intends
Sapience issued shares of its common stock in the financing. The proceeds of the financing will fund the development of Sapience's lead drug candidate, ST-36, which selectively targets
On October 9, 2015, an ODD was granted by the European Commission to NLS for Mazindol within the same indication. ODD provides incentives such as tax credits, user
The agreement gives Cantabio access to intellectual property derived from the joint research done at Purdue University and Cantabio, further strengthening the company’s intellectual property position in DJ-1
TIM-1 expression is upregulated in several cancers, most notably renal cell and ovarian carcinomas, and is associated with a more malignant phenotype of RCC and tumor progression. TIM-1
In accordance with the FDA-granted special protocol assessment, the current analysis occurred following 191 progression events. Because enrollment was interrupted by a partial clinical hold in November 2014,
The acquired portfolio includes New Skin, the #1 OTC liquid bandage brand in the U.S. It is an antiseptic which kills germs and dries rapidly to form a
CCP-08 is the third extended-release product being developed for Vernalis by Tris Pharma ("Tris") for the US prescription cough-cold market. The first product, Tuzistra XR was approved by the FDA in April 2015 and was
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.